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harvests. In addition, this prediction model will enable us to
identify additional genetic determinants for collection efﬁ-
ciency in bone marrow.439
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Background: Despite the progress of antiviral therapy in
recent years, CMV infection continues to be a major
complication after allogeneic hematopoietic cell trans-
plantation (HCT). We aimed to study the risk factors for ﬁrst
and subsequent CMV infections among patients who are
CMV seropositive.
Methods: we analyzed all sequential CMV seropositive pa-
tients that were given allogeneic HCT in a single center. We
tested the impact of a variety of patients and trans-
plantation’s characteristics on both ﬁrst and subsequent
CMV reactivations. Signiﬁcant factors identiﬁed on multi-
variate analyses were entered intomodels to predict ﬁrst and
subsequent CMV reactivation.
Results: Between May 2007 and December 2012, 121 CMV
seropositive patients were given allograft. Multivariate
model identiﬁed myeloablative preparative regimen
(HR¼4.297, p¼.033) and acute GVHD prior to infection
(HR¼5.091, p¼.021) as risk factors for ﬁrst CMV infection.
The cumulative incidences of ﬁrst CMV infection for patients
with 0, 1 and 2 risk factors were 52%, 71% and 91%, respec-
tively, Figure. Receiver operating curves for the model
showed for one risk factor a sensitivity of 84% and speciﬁcity
of 34% and for 2 risk factors 41% and 91%, respectively.
Multivariate analysis identiﬁed the diagnosis of lymphoma/
myeloma (HR¼3.5, p¼.049) and GVHD (HR¼1.280, p¼.045)
as risk factors for subsequent CMV infection. High graft CD3
stem cell dose was protective (HR¼0.543, p¼.056). The cu-
mulative incidences for subsequent CMV reactivation in pa-
tients with 0, 1, and 2-3 risk factors were 11%, 43% and 77%,
respectively. Receiver operating curves for the model
showed for one risk factor a sensitivity of 67% and speciﬁcity
of 90% and for more than 2 risk factors 93% and 47%,
respectively.Figure.Conclusions: In CMV seropositive patients, myeloablative
conditioning and acute GVHD are risk factors for ﬁrst CMV
infection and lymphoma/myeloma, ongoing GVHD and low
CD3 graft content are risk factors for a subsequent in-
fection.440
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UCBT has high early transplant-related mortality. We
explored the feasibility of using related, mismatched, and
unmanipulated bone marrow as third party donor graft with
the addition of post-transplant cyclophosphamide (PtCy) for
unrelated single unit UCBT (dual transplants). Our aimwas to
decrease UCBT early mortality without increasing aGvHD.
We compared 16 cases of dual transplant (09/2012-08/14,
center 1) with two single UCBT historical groups; one with
PtCy (20 cases, 07/2010-08/12, center 1 & 2), and a 2nd
without PtCy (31 cases, 03/2010-07/12, center 2). We did not
include Fanconi and dyskeratosis congenita patients. The
main features of this dual platform were; 1. Pre-transplant
rATG (7 mg/kg/total dose) with Rituximab (100 mg/m2/total
dose), 2. Related bone marrow graft stimulated with 3 days
G-CSF and 3. PtCy on days +3 and +4 (100 mg/kg/total dose).
We used this core for bothmyeloablative (59%) and RIC UCBT.
In the ﬁrst 11 cases, CSA and MMF were started at day +5. In
the other 6 patients, we used sirolimus before transplant
(day -6) and MMF (day +5). To estimate adjusted hazards
rates (HR) by transplant group we carried out Cox’s multi-
variate regression models clustered by transplant year.
Covariates included in the models were: age, sex, RIC, HLA
match, CMV receptor status, pre-freezing total nucleated
cells (TNC), CD34, female:male receptor:donor mismatch.
Receptors in the dual group were older (median age (yrs)
12.1 vs 6.0 vs 6.7; P<0.01). Median CB TNC and CD34 cells
infused for dual, with and without PtCy were 5.7 vs 6.7 vs
5.4x107/kg (P¼0.08), and 2.2 vs 2.7 vs 2.7x105/kg (P¼0.45),
respectively. Dual, PtCy, and non-PtCy groupsmedian time to
neutrophil and platelet engraftment was 18.5 vs 25 vs 17
days (P¼0.07), and 19 vs 40.5 vs 33 (P¼0.01), respectively.
Grades II-IV aGvHD for each group was 47%, 31%, and 56%
(P¼0.30). There were no cases of grade IV aGvHD in the dual
or the PtCy group. Acute leukemia 12 months cumulative
relapse was 6% for dual compared with the other 2 groups
(32% and 33%, P¼0.12). Cumulative 100-daymortality was 7%
for dual compared with 23% and 28% for the other two co-
horts (P¼0.1). Using the non-PtCy cohort as referent, 100-day
mortality HR was 0.2 (95%CI: 0.1, 0.6) for dual and 0.9 (95%CI:
0.2, 5.2) for the PtCy group. One-year HR was 0.6 (95%CI: 0.3,
1.5) for dual, and 0.9 (95%CI: 0.3, 2.9) for the PtCy group.
Overall, PtCy-dual transplant approach decreases 100-day
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fect was independent of other relevant variables. The shorter
time to neutrophil and platelet engraftment and no increase
of aGVHD could explain the decrease in early mortality. The
impact of this approach over cGvHD and long-termmortality
is uncertain at this moment; nevertheless, we have no evi-
dence of increased relapse in acute leukemia. Although
further studies are necessary, dual-PtCy could be an alter-
native for patients without matched sibling donor.441
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Introduction: Haploidential hematopoietic cell trans-
plantation (haplo HCT) with post transplant cyclophospha-
mide is a treatment option for hematologic cancers. Higher
accessibility and lower costs compared to other alternative
donors are just two advantages. Studies have shown beneﬁts
in survival, toxicity and acute and chronic graft vs host dis-
ease (GVHD) risks. Since our population is underrepresented
in international registries, haplo HCT will signiﬁcantly in-
crease the possibility of transplanting patients in need.
Patients and Methods: Retrospective analysis of patients
with hematologic cancers who underwent haplo HCT in 2
high complexity hospitals in Santiago, Chile, between 2012
and 2014. We describe demographics, overall survival (OS),
progression free survival (PFS), acute and chronic GVHD,
neutrophil and platelet engraftment and transplant compli-
cations. Statistical analysis was performed with GraphPad
6.0f software.
Results: 18 patients were transplanted, with a median age of
36 years old (range, 17 - 57), and 73% males (n¼13). 73%
(n¼13) had acute leukemias, 17% (n¼3) non-Hodgkin lym-
phomas and 7% (n¼1) Hodgkin lymphoma. 55% (n¼10) were
in ﬁrst complete remission (CR1), 39% (n¼7) in second
complete remission (CR2) and 5% (n¼1) in third complete
remission (CR3). 89% (n¼16) of the donors were 3/6 HLA
compatible and 11% (n¼2) 4/6 HLA compatible (intermediate
resolution in A, B and DRB1). 56% (n¼10) were conditioned
with myeloablative (MA) regimens. All received tacrolimus,
mycophenolate mophetil and posttransplant cyclophospha-
mide as GVHD prophylaxis. The median CD34+ cell dose
(106/kg of the receptor) was 6.01 (range, 1.6 - 9.5) obtained in
89% of the cases (n¼15) by leukopheresis. Themedian time to
neutrophil engraftmentwas 18.1 days (range,12 - 25)without
differences between MA and reduced intensity conditioning
(RIC) regimens. Median time to platelet engraftment was 34
days (range,14 - 150) with greater engraftment time after MA
(median: 43 days) than RIC (median: 29 days). Incidence of
grade 2-4 and 3-4 acute GVHDwas 22% (n¼4) and 17% (n¼3),
respectively. No cases of chronic GVHD have been diagnosed.
Main complications after transplant include 1 patient with
sinusoidal obstruction syndrome, 1 with hemodialysis, 11
with CMV reactivation and 8 with other infections (BK virus,
C. difﬁcile, Fusarium sp and VRE). The median follow up time
was 228 days (range, 45 - 565) and 1 year OS and PFS were
56% and 59%, respectively. No differences in OS were seenwhen comparing patients transplanted in CR1 and CR2 (66%
vs 57%, p¼NS). Transplant related mortality (TRM) was 29%
after 1 year of follow-up.
Conclusions: Haplo HCT is a procedure that offers a curative
alternative to patients who lack matched donors. In this ﬁrst
report from Chile, we observed similar outcomes to other
reports. Further follow-up and more patients are needed to
better evaluate this procedure in the long-term.442
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Cyclosporine and tacrolimus given intravenously bind to the
venous access device (VAD) used for infusion, and if sampled
from the same site result in false high levels. Central VAD
lumen contamination in a patient with sub-therapeutic levels
of tacrolimusprompted thenursing staff to investigate infusion
and blood sampling practices. Details on both the infusion and
blood sampling for all inpatients receiving intravenous (IV)
cyclosporine and tacrolimus on the adult transplant unit were
documented in the electronic medical record. The names of
both nurses conﬁrming at the bedside correct connection of
the labeled IV tubing to the dedicated, labeled lumen were
recorded. For both infusions and blood sampling for trough
levels the VAD and lumen color were documented.
Accidental contamination was deﬁned as a drug infusing
incorrectly through a lumen that was not dedicated and
labeled on the VAD. Over a period of ﬁve months, eleven pa-
tients received intravenous infusions of cyclosporine and nine
patients received intravenous tacrolimus. There were no
accidental contaminations during this period. Despite no
accidental contaminations, blood sampling results from non-
dedicated lumens of central VADs for patients receiving
tacrolimus were elevated when compared to results obtained
peripherally. These patients had blood trough levels obtained
through central and peripheral routes for comparison weekly.
All patients had elevated levels of tacrolimus from the non-
infusion lumen(s) of the central VAD despite documentation
conﬁrming that the drug had been infused through the dedi-
cated lumen and levels were obtained correctly. This was not
the case for any of the 11 patients receiving cyclosporine.
A review of the literature reveals similar results, based on
studies of cyclosporine and tacrolimus levels obtained from
both central and peripheral sources, showing cross
contamination of lumens within the same VAD for patients
receiving tacrolimus but none for cyclosporine. Possible
reasons for cross contamination are reported as being due to
the properties of tacrolimus or cross contamination of the
drug at the exit site of the distal end of individual lumens.
Nursing practice has not changed with regards to patients
receiving intravenous cyclosporine. A change in practice for
patients receiving tacrolimus infusions was made standard-
izing the use of the distal lumen of a staggered VAD as
dedicated for infusion. Evidence suggests that incompatible
drugs do not precipitate if infused through staggered lumens
as the drugs do not have time tomix at the exit site. Since this
change in practice, no cross contamination with tacrolimus
has occurred. This option allows patients to avoid peripheral
venipuncture. Other centers may consider this for their pa-
tients if they also ﬁnd that use of staggered lines yields
consistently reliable levels.
